TABLE 1.
Antimicrobial drug susceptibility profiles.
| Antibiotics | MIC (mg/L)/antimicrobial susceptibility |
||||||||||||
| Transformants |
Transconjugants |
||||||||||||
| 1678 | Top10 | J53 | p1678–6-TOP10 (TetA) |
p1678-3 Top10 (FosA3) |
p1678-4-Top10 (NDM-5) |
p1678-5-Top10 (MCR-1) |
p1678-3-J53 (FosA3) |
p1678-4-J53 (NDM-5) |
p1678-5-J53 (MCR-1) |
p1678-3 and 5-J53 (FosA3+MCR-1) |
p1678-4 and 5-J53 (NDM-5+MCR-1) |
p1678-3 and 4 and 5-J53 (FosA3+NDM-5+MCR-1) |
|
| MEM | >16/R | ≤0.06/S | ≤0.06/S | ≤0.06/S | ≤0.06/S | 16/R | ≤0.06/S | ≤0.06/S | 16/R | ≤0.06/S | ≤0.06/S | 16/R | 16/R |
| IPM | 16/R | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | 4/R | ≤0.25/S | ≤0.25/S | 4/R | ≤0.25/S | ≤0.25/S | 8/R | 8/R |
| ETP | >2/R | ≤0.015/S | ≤0.015/S | ≤0.015/S | ≤0.015/S | >2/R | ≤0.015/S | ≤0.015/S | >2/R | ≤0.015/S | ≤0.015/S | >2/R | >2/R |
| Caz/AVI | >16/4/R | ≤0.5/4/S | ≤0.5/4/S | ≤0.5/4/S | ≤0.5/4/S | >16/4/R | ≤0.5/4/S | ≤0.5/4/S | >16/4/R | ≤0.5/4/S | ≤0.5/4/S | >16/4/R | >16/4/R |
| TGC | 8/R | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S |
| POL | 16/R | 0.25/S | 0.25/S | 0.25/S | 0.25/S | 0.25/S | 16/R | 0.25/S | 0.25/S | 16/R | 16/R | 16/R | 16/R |
| FOS | >256/R | 0.25/S | 0.25/S | 0.25/S | >256/R | 0.25/S | 0.25/S | >256/R | 0.25/S | 0.25/S | >256/R | 0.25/S | >256/R |
| AMP | >32/R | ≤8/S | ≤8/S | ≤8/S | >32/R | >32/R | ≤8/S | >32/R | >32/R | ≤8/S | >32/R | >32/R | >32/R |
| CZO | >32/R | ≤2/S | ≤2/S | ≤2/S | >32/R | >32/R | ≤2/S | >32/R | >32/R | ≤2/S | >32/R | >32/R | >32/R |
| CAZ | >128/R | ≤0.25/S | ≤0.25/S | ≤0.25/S | >128/R | >128/R | ≤0.25/S | >128/R | >128/R | ≤0.25/S | >128/R | >128/R | >128/R |
| FEP | >16/R | ≤0.5/S | ≤0.5/S | ≤0.5/S | ≤0.5/S | >16/R | ≤0.5/S | ≤0.5/S | >16/R | ≤0.5/S | ≤0.5/S | >16/R | >16/R |
| CSL | >64/32/R | ≤16/8/S | ≤16/8/S | ≤16/8/S | ≤16/8/S | >64/32/R | ≤16/8/S | ≤16/8/S | >64/32/R | ≤16/8/S | ≤16/8/S | >64/32/R | >64/32/R |
| SAM | >32/16/R | ≤16/4/S | ≤16/4/S | ≤16/4/S | ≤16/4/S | >32/16/R | ≤16/4/S | ≤16/4/S | >32/16/R | ≤16/4/S | ≤16/4/S | >32/16/R | >32/16/R |
| FOX | >32/R | ≤8/S | ≤8/S | ≤8/S | ≤8/S | >32/R | ≤8/S | ≤8/S | >32/R | ≤8/S | ≤8/S | >32/R | >32/R |
| CXM | >16/R | 8/S | 8/S | 8/S | >16/R | >16/R | 8/S | >16/R | >16/R | 8/S | >16/R | >16/R | >16/R |
| CTX | >64/R | ≤0.12/S | ≤0.12/S | ≤0.12/S | 64/R | >64/R | ≤0.12/S | 64/R | >64/R | ≤0.12/S | 64/R | >64/R | >64/R |
| TZP | >128/4/R | ≤16/4/S | ≤16/4/S | ≤16/4/S | ≤16/4/S | >128/4/R | ≤16/4/S | ≤16/4/S | >128/4/R | ≤16/4/S | ≤16/4/S | >128/4/R | >128/4/R |
| AMC | >32/16/R | ≤8/4/S | ≤8/4/S | ≤8/4/S | ≤8/4/S | >32/16/R | ≤8/4/S | ≤8/4/S | >32/16/R | ≤8/4/S | ≤8/4/S | >32/16/R | >32/16/R |
| LVX | >8/R | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S | ≤0.12/S |
| MFX | >2/R | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S | ≤0.25/S |
| TCY | >16/R | ≤2/S | ≤2/S | 16/R | ≤2/S | ≤2/S | ≤2/S | ≤2/S | ≤2/S | ≤2/S | ≤2/S | ≤2/S | ≤2/S |
| GEN | 16/R | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S | ≤1/S |
| AMK | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S |
| ATM | >16/R | ≤4/S | ≤4/S | ≤4/S | >16/R | ≤4/S | ≤4/S | >16/R | ≤4/S | ≤4/S | ≤4/S | ≤4/S | >16/R |
| NIT | 64/I | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S | ≤16/S |
| SXT | >4/76/R | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S | ≤0.5/9.5/S |
MEM, Meropenem; IPM, Imipenem; ETP, Ertapenem; Caz/AVI, ceftazidime–avibactam; TGC, Tigecycline; POL, Polymixin B; FOS, Fosfomycin; AMP, Ampicillin; CZO, Cefazolin; CAZ, Ceftazidime; FEP, Cefepime; CSL, Cefoperazone/Sulbactam; SAM, Ampicillin/Sulbactam; FOX, Cefoxitin; CXM, Cefuroxime; CTX, Cefotaxime; TZP, Piperacillin/Tazobactam; AMC, Amoxicillin/Clavulanic acid; LVX, Levofloxacin; MFX, Moxifloxacin; TCY, Tetracycline; GEN, Gentamicin; AMK, Amikacin; ATM, Aztreonam; NIT, Nitrofurantoin; SXT, Trimethoprim/Sulfamethoxazole. The other resistance phenotype like LVX, MFX, GEN, NIT, or SXT resistance did not present in these transformants or transconjugants in table because these elements are located on p1678-2 plasmid, not p16783-3(fosA3), p1678-4(blaNDM–5), p1678-5(mcr-1), and p1678-6(tetA). The bold values indicated important resistance genes and resistance phenotypes.